2 active not recruiting, 2 unknown. 4 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Active not recruiting 2, Unknown 2 |
| Phase 2 | 2 | Active not recruiting 2 |
Follow High Grade B-Cell Lymphoma, Not Otherwise Specified: new trials by email Literature Review of High Grade B-Cell Lymphoma, Not Otherwise Specified trials Research Report on High Grade B-Cell Lymphoma, Not Otherwise Specified
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 422 | 2021-05-20 | 2026-10-27 |
| Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies - High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified | Phase 3 | Unknown | Shandong Provincial Hospital | 130 | 2021-04-15 | 2021-11-19 |
| Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX, R-CHOP; R-DA-EPOCH; R-HD MTX - High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | Phase 3 | Unknown | Shandong Provincial Hospital | 160 | 2021-03-01 | 2021-12-21 |
| Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 363 | 2019-10-22 | 2026-10-26 |
Lymphoma, Large B-Cell, Diffuse (4) · Lymphoma, Mantle-Cell (2) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1)
Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoma (4) · Lymphoma, Non-Hodgkin (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Lymphoma, B-Cell (3)
CT-P10 (2) · Cyclophosphamide (2) · Doxorubicin (2) · Magnetic Resonance Spectroscopy (2) · Prednisone (2) · Rituximab (2) · Specimen Handling (2) · Vincristine (2) · deltacortene (2) · prednylidene (2) · Azacitidine (1) · Biopsy (1) · Etoposide (1) · Hyaluronoglucosaminidase (1) · Spinal Puncture (1)
National Cancer Institute (NCI) (2) · Shandong Provincial Hospital (2)
China (2) · United States (2)
Xin Wang, PhD (2) · Elizabeth A Brem (1) · Jeremy S Abramson (1)
PMID 34634256, PMID 34686472, PMID 42660130
U10CA180821 (1), U10CA180888 (1)